A pathomorphological study on the diabetogenic drug-induced heart disease in the rat

1983 ◽  
pp. 70-77
Author(s):  
Shunzo Onishi ◽  
H. Nunotani ◽  
Y. Tochino
Keyword(s):  
Heart Disease ◽  
Drug Induced

scholarly journals Role of Serotoninergic Pathways in Drug-Induced Valvular Heart Disease and Diagnostic Features by Echocardiography

2009 ◽  
Vol 22 (8) ◽  
pp. 883-889 ◽  
Author(s):  
Sakima A. Smith ◽  
Alan D. Waggoner ◽  
Lisa de las Fuentes ◽  
Victor G. Davila-Roman
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Drug Induced ◽  
Diagnostic Features

scholarly journals Benfluorex: the last chapter of drug-induced valvular heart disease?

2010 ◽  
Vol 12 (4) ◽  
pp. 263-264 ◽  
Author(s):  
S. Droogmans ◽  
B. Cosyns ◽  
G. Van Camp
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Drug Induced

Republished: Drug-induced valvular heart disease

2013 ◽  
Vol 89 (1049) ◽  
pp. 173-178 ◽  
Author(s):  
Bernard Cosyns ◽  
Steven Droogmans ◽  
Raphael Rosenhek ◽  
Patrizio Lancellotti
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Drug Induced

scholarly journals Drug-Induced- or Rheumatic- Valvular Heart Disease in Patients Exposed to Benfluorex?

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0160011 ◽  
Author(s):  
Florent Le Ven ◽  
Zarrin Alavi ◽  
Yannick Jobic ◽  
Yves Etienne ◽  
Romain Didier ◽  
...  
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Drug Induced

Drug-induced valvular heart disease

Heart ◽  
2012 ◽  
Vol 99 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Bernard Cosyns ◽  
Steven Droogmans ◽  
Raphael Rosenhek ◽  
Patrizio Lancellotti
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
Drug Induced

scholarly journals In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology

2007 ◽  
Vol 28 (17) ◽  
pp. 2156-2162 ◽  
Author(s):  
S. Droogmans ◽  
P. R. Franken ◽  
C. Garbar ◽  
C. Weytjens ◽  
B. Cosyns ◽  
...  
Keyword(s):  
Heart Disease ◽  
Valvular Heart Disease ◽  
In Vivo Model ◽  
Drug Induced

scholarly journals Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations

2017 ◽  
Vol 45 (3) ◽  
pp. 381-388 ◽  
Author(s):  
Thomas Papoian ◽  
Gowraganahalli Jagadeesh ◽  
Muriel Saulnier ◽  
Natalie Simpson ◽  
Arippa Ravindran ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Heart Disease ◽  
Valvular Heart Disease ◽  
Serotonin Receptor ◽  
Term Treatment ◽  
In Vitro Assays ◽  
Drug Induced ◽  
Safety Margins ◽  
Long Term Treatment

Drug-induced valvular heart disease (VHD) is a serious side effect linked to long-term treatment with 5-hydroxytryptamine (serotonin) receptor 2B (5-HT2B) agonists. Safety assessment for off-target pharmacodynamic activity is a common approach used to screen drugs for this undesired property. Such studies include in vitro assays to determine whether the drug is a 5-HT2B agonist, a necessary pharmacological property for development of VHD. Measures of in vitro binding affinity (IC50, Ki) or cellular functional activity (EC50) are often compared to maximum therapeutic free plasma drug levels ( fCmax) from which safety margins (SMs) can be derived. However, there is no clear consensus on what constitutes an appropriate SM under various therapeutic conditions of use. The strengths and limitations of SM determinations and current risk assessment methodology are reviewed and evaluated. It is concluded that the use of SMs based on Ki values, or those relative to serotonin (5-HT), appears to be a better predictor than the use of EC50 or EC50/human fCmax values for determining whether known 5-HT2B agonists have resulted in VHD. It is hoped that such a discussion will improve efforts to reduce this preventable serious drug-induced toxicity from occurring and lead to more informed risk assessment strategies.

Calcifications in Benfluorex-Induced Valve Heart Disease: A Misknown Association

Cardiology ◽  
2015 ◽  
Vol 130 (2) ◽  
pp. 87-90 ◽  
Author(s):  
François Plurien ◽  
Patrick Bruneval ◽  
Yannick Jobic ◽  
Bernard Iung ◽  
Pierre-Vladimir Ennezat
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Mitral Regurgitation ◽  
A Priori ◽  
Valvular Disease ◽  
Valvular Regurgitation ◽  
Drug Induced ◽  
Documented Case ◽  
Valve Heart Disease

Benfluorex, an anorexigenic agent, is recognized to induce noncalcified restrictive valvular regurgitation. We report a well-documented case of a 73-year-old patient who developed heart failure with aortic and mitral regurgitation following benfluorex intake. Echocardiography and peroperative analysis found large mitral annular calcifications and aortic subvalvular calcifications. Pathology confirmed drug-induced valve heart disease (DIVHD). The presence of valvular apparatus calcification should not lead to diagnosis of degenerative valvular disease and a priori preclude the diagnosis of DIVHD.

Sign in / Sign up

Export Citation Format

Share Document